Replies to post #277846 on Anavex Life Sciences Corp (AVXL)

[boi568]

https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf

Page 9 of the pdf indicates that for all indications, the success rate of Phase 3 to NDA/BLA is 58.1%, and for neurology the rate is 57.4%.

That is what I was referring to.